Table 3.
Results of differing biopsy strategies per 1000 men screened at varying thresholds for risk of any-grade cancer or high-grade cancer among men with anticoagulated plasma
| Threshold | Biopsies | Any-grade prostate cancer | Gleason score 7 or higher (high-grade) | Primary Gleason score 4 or higher* | ||||
|---|---|---|---|---|---|---|---|---|
| Performed | Avoided (%) | Found | Delayed | Found | Delayed | Found | Delayed | |
| Risk of any-grade cancer | ||||||||
| Biopsy all men | 1000 | 0 (0) | 364 | 0 | 133 | 0 | 47 | 0 |
| Risk by age and total PSA | ||||||||
| ≥20% | 997 | 3 (0.3) | 363 | 0 | 133 | 0 | 47 | 0 |
| ≥30% | 642 | 358 (36) | 264 | 99 | 111 | 22 | 41 | 6 |
| Risk by age and panel of four kallikrein markers | ||||||||
| ≥20% | 834 | 166 (17) | 334 | 30 | 129 | 4 | 46 | 1 |
| ≥30% | 545 | 455 (46) | 264 | 100 | 116 | 17 | 43 | 4 |
| Risk of high-grade cancer | ||||||||
| Biopsy all men | 1000 | 0 (0) | 364 | 0 | 133 | 0 | 47 | 0 |
| Risk by age and total PSA | ||||||||
| ≥4% | 974 | 26 (2.6) | 357 | 7 | 132 | 1 | 47 | 0 |
| ≥6% | 876 | 124 (12) | 332 | 32 | 127 | 6 | 44 | 3 |
| ≥8% | 715 | 285 (28) | 284 | 79 | 117 | 16 | 42 | 5 |
| ≥10% | 533 | 467 (47) | 235 | 129 | 105 | 28 | 39 | 8 |
| Risk by age and panel of four kallikrein markers | ||||||||
| ≥4% | 734 | 266 (27) | 313 | 51 | 127 | 6 | 46 | 1 |
| ≥6% | 572 | 428 (43) | 270 | 94 | 119 | 14 | 43 | 4 |
| ≥8% | 442 | 558 (56) | 229 | 135 | 110 | 23 | 42 | 5 |
| ≥10% | 361 | 639 (64) | 203 | 161 | 103 | 30 | 39 | 8 |
* Includes cases with any Gleason Grade 5 component.